JP2015511221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511221A5 JP2015511221A5 JP2014553763A JP2014553763A JP2015511221A5 JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5 JP 2014553763 A JP2014553763 A JP 2014553763A JP 2014553763 A JP2014553763 A JP 2014553763A JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fxii
- pharmaceutical composition
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592652P | 2012-01-31 | 2012-01-31 | |
| EP12153341.8A EP2623110A1 (en) | 2012-01-31 | 2012-01-31 | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| EP12153341.8 | 2012-01-31 | ||
| US61/592,652 | 2012-01-31 | ||
| PCT/EP2013/051832 WO2013113774A1 (en) | 2012-01-31 | 2013-01-31 | Factor xii inhibitors for the treatment of neurological inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511221A JP2015511221A (ja) | 2015-04-16 |
| JP2015511221A5 true JP2015511221A5 (enExample) | 2016-01-14 |
| JP6243854B2 JP6243854B2 (ja) | 2017-12-06 |
Family
ID=45554534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553763A Active JP6243854B2 (ja) | 2012-01-31 | 2013-01-31 | 神経炎症性障害の処置のための第ｘｉｉ因子阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9957329B2 (enExample) |
| EP (2) | EP2623110A1 (enExample) |
| JP (1) | JP6243854B2 (enExample) |
| KR (1) | KR102067394B1 (enExample) |
| CN (1) | CN104080470B (enExample) |
| AU (1) | AU2013200498B2 (enExample) |
| CA (1) | CA2862903C (enExample) |
| DK (1) | DK2809336T3 (enExample) |
| ES (1) | ES2687018T3 (enExample) |
| PL (1) | PL2809336T3 (enExample) |
| WO (1) | WO2013113774A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2646191T3 (es) | 2011-03-09 | 2017-12-12 | Csl Behring Gmbh | Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales |
| JP6636334B2 (ja) | 2013-03-08 | 2020-01-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 遠隔虚血再灌流傷害の治療および予防 |
| BR112016010837A8 (pt) | 2013-11-13 | 2020-04-22 | Shire Viropharma Inc | uso de uma composição compreendendo um inibidor de c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits |
| BR112016029624A2 (pt) | 2014-06-18 | 2017-10-24 | Csl Behring Gmbh | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| KR101744959B1 (ko) * | 2014-12-05 | 2017-06-12 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| IL253180B2 (en) | 2015-01-02 | 2023-04-01 | Dyax Corp | Bispecific antibodies against plasma kallikrein and factor xii |
| WO2016114386A1 (ja) * | 2015-01-15 | 2016-07-21 | 国立研究開発法人国立精神・神経医療研究センター | 進行型免疫性脱髄疾患治療剤 |
| KR102794955B1 (ko) | 2015-07-21 | 2025-04-15 | 다케다 파머수티컬 컴패니 리미티드 | Xiia 인자의 단일클론 항체 저해제 |
| BR112018014810A2 (pt) | 2016-01-22 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-fator xi de coagulação |
| KR20230136687A (ko) * | 2016-04-06 | 2023-09-26 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| IL269893B2 (en) | 2017-05-15 | 2023-10-01 | Stem Cell Medicine Ltd | Treatment of multiple sclerosis with adipose-derived stem cells |
| CA3062964C (en) | 2017-05-15 | 2024-11-12 | Mapi Pharma Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMER AND ADIPE-DERIVED STEM CELLS |
| CN111479587B (zh) * | 2017-12-15 | 2024-01-09 | 杰特有限公司 | FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用 |
| MA52966A (fr) | 2018-06-19 | 2021-04-28 | Regeneron Pharma | Anticorps anti-facteur xii/xiia et leurs utilisations |
| US20240352150A2 (en) * | 2020-06-16 | 2024-10-24 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
| CN121568964A (zh) | 2023-07-19 | 2026-02-24 | 里珍纳龙药品有限公司 | 抗因子XII/XIIa抗体及其用途 |
| CN120192392B (zh) * | 2025-05-23 | 2025-09-05 | 昆明医科大学 | 一种版纳绳蚋抗栓肽Sibakazin及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DE69233069T2 (de) | 1991-03-15 | 2003-11-27 | Amgen Inc., Thousand Oaks | Pegylation von polypeptiden |
| EP0793504B1 (en) | 1994-12-12 | 2005-06-08 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| GB9800817D0 (en) * | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| EP1573339A2 (en) | 2002-12-20 | 2005-09-14 | Axis-Shield Diagnostics Limited | Detection or determination of variants of factor xiia |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| PT1624891E (pt) | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EA008831B1 (ru) | 2003-06-12 | 2007-08-31 | Эли Лилли Энд Компани | Слитые белки аналогов glp-1 |
| WO2005024044A2 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| WO2005063808A1 (en) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| WO2006033386A1 (ja) | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP5118492B2 (ja) * | 2004-12-23 | 2013-01-16 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血栓の形成の防止および／または安定化の防止 |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| NZ576195A (en) * | 2006-10-10 | 2012-04-27 | Az Univ Amsterdam | Complement inhibition for improved nerve regeneration |
| ES2753183T3 (es) * | 2007-02-12 | 2020-04-07 | Csl Behring Gmbh | Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| WO2010085682A2 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| FI2734552T3 (fi) * | 2011-07-22 | 2025-02-12 | Csl Behring Gmbh | Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö |
-
2012
- 2012-01-31 EP EP12153341.8A patent/EP2623110A1/en not_active Ceased
-
2013
- 2013-01-31 US US14/374,300 patent/US9957329B2/en active Active
- 2013-01-31 KR KR1020147024214A patent/KR102067394B1/ko active Active
- 2013-01-31 EP EP13701651.5A patent/EP2809336B1/en active Active
- 2013-01-31 CN CN201380007416.XA patent/CN104080470B/zh active Active
- 2013-01-31 AU AU2013200498A patent/AU2013200498B2/en active Active
- 2013-01-31 WO PCT/EP2013/051832 patent/WO2013113774A1/en not_active Ceased
- 2013-01-31 ES ES13701651.5T patent/ES2687018T3/es active Active
- 2013-01-31 PL PL13701651T patent/PL2809336T3/pl unknown
- 2013-01-31 JP JP2014553763A patent/JP6243854B2/ja active Active
- 2013-01-31 DK DK13701651.5T patent/DK2809336T3/en active
- 2013-01-31 CA CA2862903A patent/CA2862903C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511221A5 (enExample) | ||
| AU2018260845B2 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| CA2901225C (en) | Treatment and prevention of remote ischemia-reperfusion injury | |
| TWI585103B (zh) | 抗ｂａｆｆ抗ｉｌ－１７雙特異性抗體 | |
| AU2014301041B2 (en) | Combination therapy using a Factor XII inhibitor and a C1-Inhibitor | |
| JP2022023049A (ja) | バイオ医薬組成物 | |
| JP2013517783A5 (enExample) | ||
| JP4638035B2 (ja) | ヒト抗−ＩＸ／ＩＸａ因子抗体 | |
| JP2019506839A5 (enExample) | ||
| JP2013542914A5 (enExample) | ||
| JP2015510875A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| CA2795168A1 (en) | Factor xii inhibitors for treating interstitial lung disease | |
| KR20160089368A (ko) | 자가면역 질환의 진단 및 치료 | |
| WO2018039514A1 (en) | Antibody-mediated neutralization of ebolaviruses | |
| CA3184718A1 (en) | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| JP2017524675A5 (enExample) | ||
| CN106029884B (zh) | 新型抗人pai-1抗体 | |
| JP2013539354A5 (enExample) | ||
| KR102558891B1 (ko) | 항―ｉｌ４―ｉｌ１３ ２특이성 항체 | |
| Bally et al. | Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoprotein | |
| KR20230030644A (ko) | 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드 | |
| US20240301073A1 (en) | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | |
| JP2019055949A5 (enExample) | ||
| Neves-Ferreira et al. | Natural inhibitors of snake venom metallopeptidases | |
| JP7685957B2 (ja) | プロテアーゼネキシン－１に対する立体構造的な単一ドメイン抗体及びその使用 |